Thyroid Monitoring After Intravascular Iodinated Contrast Media in Infants and Children Through 3 Years of Age
Ryan S. Miller·Ari J. Wassner·Matthew A. Crystal·Kathleen Bethin·Catherine A. Dinauer·Monica Forbes-Amrein·Brent M. Gordon·Bridget Hughes·Amit Lahoti·Audrey C. Marshall·Lucy D. Mastrandrea·Liuska Pesce·Robert Rapaport·Arash Salavitabar·Jonathan D. Wasserman·Andrew J. Bauer·Jonathan R. Dillman
In March 2022, the US Food and Drug Administration issued a drug safety communication (DSC) recommending monitoring of thyroid function in children up to 3 years of age who receive intravascular injection of iodinated contrast media (IV ICM) for medical imaging. In response, a group of pediatric and imaging experts convened to review the current scientific evidence on thyroid dysfunction after IV ICM and to provide recommendations on thyroid testing and management after IV ICM administration in